Protein Summary
Integrin alpha-3/beta-1 is a receptor for fibronectin, laminin, collagen, epiligrin, thrombospondin and CSPG4. Integrin alpha-3/beta-1 provides a docking site for FAP (seprase) at invadopodia plasma membranes in a collagen-dependent manner and hence may participate in the adhesion, formation of invadopodia and matrix degradation processes, promoting cell invasion. Alpha-3/beta-1 may mediate with LGALS3 the stimulation by CSPG4 of endothelial cells migration. The gene encodes a member of the integrin alpha chain family of proteins. Integrins are heterodimeric integral membrane proteins composed of an alpha chain and a beta chain that function as cell surface adhesion molecules. The encoded preproprotein is proteolytically processed to generate light and heavy chains that comprise the alpha 3 subunit. This subunit joins with a beta 1 subunit to form an integrin that interacts with extracellular matrix proteins including members of the laminin family. Expression of this gene may be correl ...more
- ENST00000007722
- ENSP00000007722
- ENSG00000005884
- ENST00000320031
- ENSP00000315190
- MSK18
- VL3A
- CD49C
- FRP-2
- GAPB3
- ILNEB
- MSK18
- VCA-2
- VLA3a
- GAP-B3
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
PubMedID | 0.95 | ||
biological process | 0.91 | ||
transcription factor perturbation | 0.88 | ||
disease perturbation | 0.79 | ||
cellular component | 0.78 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 210.84 (req: < 5)
Gene RIFs: 151 (req: <= 3)
Antibodies: 933 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 210.84 (req: >= 5)
Gene RIFs: 151 (req: > 3)
Antibodies: 933 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 35
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 1
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0